Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
San Francisco, Modesto, Palo Alto/Santa Cruz, Greater Sacramento Valley, Santa Rosa, East Bay, San Mateo, Solano/Vallejo
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
SWOG S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (PM2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Principal Investigator
Related Studies
Impact of COVID-19 on Cancer Care Management
Study will enhance understanding of cancer care management due to COVID-19.
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Breast Cancer Chemoprevention in Primary Care at Geisinger
Identify PCPs’ awareness of breast cancer risk assessment and breast cancer chemoprevention knowledge, and identify perceived barriers and clinic solutions.
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator
Dana Farber 13-09-259 DCIS Registry
Molecular Characterization of Breast Cancer with Duct Forming Features
Investigator: Kristie A. Bobolis, M.D.